Sequential Cohort Analysis After Liver Transplantation Shows De Novo Extended Release Tacrolimus Is Safe, Efficacious, and Minimizes Renal Dysfunction

Overview

Journal Transplant Direct

Publisher Wolters Kluwer

Specialty General Surgery

Date 2020 Feb 26

PMID 32095514

Citations 1

Authors

Tiong Yeng Lim

Mark J McPhail

Amar Shah

Sara Mahgoub

Jeremy Nayagam

Matthew Cramp

William Bernal

Krish Menon

Wayel Jassem

Deepak Joshi

Michael A Heneghan

Kosh Agarwal

Nigel D Heaton

Abid Suddle

John G OGrady

Varuna R Aluvihare

Affiliations

Soon will be listed here.

Abstract

Methods: We conducted a single-center, prospective sequential cohort analysis of adult patients undergoing LT during a change in protocol from de novo BDT to ERT, with a 6-month post-LT follow-up.

Results: A total of 160 transplanted patients were evaluated; 82 were in the BDT group and 78 were in the ERT group. The cohorts were matched for standard variables and a similar proportion in each group received induction interleukin-2 receptor antibody (36% and 31%). There were no significant differences in the measured outcomes of patient and graft survival, biopsy-proven acute rejection episodes, post LT diabetes, and toxicity. A significantly lower number of patients developed chronic kidney disease Stage3-4 in the ERT cohort compared with BDT cohort. In patients with pre-LT renal dysfunction who received antibody induction, estimated glomerular filtration rate decreased significantly in the BDT but not the ERT group.

Conclusions: We show that once-daily ERT is as safe and efficacious as BDT in de novo LT but optimally conserves renal function post-LT.

Citing Articles

A Systematic Review of the Literature on Chronic Kidney Disease Following Liver Transplantation.

Miyata H, Morita Y, Kumar A Ann Transplant. 2022; 27:e935170.

PMID: 35607264 PMC: 9145918. DOI: 10.12659/AOT.935170.

References

Trunecka P, Klempnauer J, Bechstein W, Pirenne J, Friman S, Zhao A . Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-The DIAMOND Study. Am J Transplant. 2015; 15(7):1843-54. PMC: 5024030. DOI: 10.1111/ajt.13182. View

Kamath P, Kim W . The model for end-stage liver disease (MELD). Hepatology. 2007; 45(3):797-805. DOI: 10.1002/hep.21563. View

Considine A, Tredger J, Heneghan M, Agarwal K, Samyn M, Heaton N . Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts. Liver Transpl. 2014; 21(1):29-37. DOI: 10.1002/lt.24022. View

Vanhove T, Vermeulen T, Annaert P, Lerut E, Kuypers D . High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. Am J Transplant. 2016; 16(10):2954-2963. DOI: 10.1111/ajt.13803. View

Trunecka P, Boillot O, Seehofer D, Pinna A, Fischer L, Ericzon B . Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant. 2010; 10(10):2313-23. DOI: 10.1111/j.1600-6143.2010.03255.x. View

van Hooff J, Alloway R, Trunecka P, Mourad M . Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies. Clin Transplant. 2010; 25(1):E1-12. DOI: 10.1111/j.1399-0012.2010.01377.x. View

Smith G . European Medicines Agency guideline on bioanalytical method validation: what more is there to say?. Bioanalysis. 2012; 4(8):865-8. DOI: 10.4155/bio.12.44. View

Gonwa T, Mai M, Melton L, Hays S, Goldstein R, Levy M . End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2002; 72(12):1934-9. DOI: 10.1097/00007890-200112270-00012. View

Gastaca M, Valdivieso A, Bustamante J, Fernandez J, Ruiz P, Ventoso A . Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: Results of a single-center cohort. Liver Transpl. 2016; 22(10):1391-400. DOI: 10.1002/lt.24514. View

10.

. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet. 1994; 344(8920):423-8. View

11.

Coilly A, Calmus Y, Chermak F, Dumortier J, Duvoux C, Guillaud O . Once-daily prolonged release tacrolimus in liver transplantation: Experts' literature review and recommendations. Liver Transpl. 2015; 21(10):1312-21. DOI: 10.1002/lt.24228. View

12.

Adam R, Karam V, Delvart V, Trunecka P, Samuel D, Bechstein W . Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant. 2015; 15(5):1267-82. DOI: 10.1111/ajt.13171. View

13.

Todo S, Fung J, Demetris A, Jain A, Venkataramanan R, Starzl T . Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc. 1990; 22(1):13-6. PMC: 2903882. View

14.

Neuberger J, Mamelok R, Neuhaus P, Pirenne J, Samuel D, Isoniemi H . Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant. 2009; 9(2):327-36. DOI: 10.1111/j.1600-6143.2008.02493.x. View

15.

Borra L, Roodnat J, Kal J, Mathot R, Weimar W, van Gelder T . High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant. 2010; 25(8):2757-63. DOI: 10.1093/ndt/gfq096. View

16.

Ojo A, Held P, Port F, Wolfe R, Leichtman A, Young E . Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003; 349(10):931-40. DOI: 10.1056/NEJMoa021744. View

17.

. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 1994; 331(17):1110-5. DOI: 10.1056/NEJM199410273311702. View

18.

Wilkinson A, Pham P . Kidney dysfunction in the recipients of liver transplants. Liver Transpl. 2005; (11 Suppl 2):S47-51. DOI: 10.1002/lt.20618. View

19.

Guitard J, Ribes D, Kamar N, Muscari F, Cointault O, Lavayssiere L . Predictive factors for chronic renal failure one year after orthotopic liver transplantation. Ren Fail. 2006; 28(5):419-25. DOI: 10.1080/08860220600683607. View

20.

Leithead J, Tariciotti L, Gunson B, Holt A, Isaac J, Mirza D . Donation after cardiac death liver transplant recipients have an increased frequency of acute kidney injury. Am J Transplant. 2012; 12(4):965-75. DOI: 10.1111/j.1600-6143.2011.03894.x. View